Dr. Anil Koul

Dr. Anil Koul |Clyto Access

Director, CSIR-IMTech, Chandigarh, India

Organizing Committee Member

Expertise: Respiratory Infections Discovery, Development of novel antiviral and antibacterial, Clinical microbiology, Pharmacology


Dr. Anil Koul, prior to taking the charge of Director, CSIR-IMTech, was Senior Director&Head, Respiratory Infections Discovery group at global healthcare giant Johnson &Johnson. He has more than 16 years of experience in pharmaceutical drug discovery research and clinical development. He obtained his Ph.D. from Max-Planck Institute for Biochemistry in Munich, Germany and Delhi University, Delhi. As a part of continued education, in 2011, he attended a short residential program at Harvard Business School, the USA on innovation, strategy, and leadership.

Dr. Anil Koul has been a key scientist in a discovery and clinical development of SIRTURO TM(generically called Bedaquiline)- the first tuberculosis drug to be granted approved byUnited State FDA and EU in last 40 years. In 2013, he was awarded “Johnson Medal”, the highest R&D prize by Johnson and Johnson for contributions to discovery and development of SIRTURO TM. Recently, he was invited to European Parliament to present to members of Europe-India Chamber of Commerce *EICC) on SIRTURO and global public health. Earlier, he was also awarded ‘The Philip B. Hofmann Prize ‘ for his discovery of SIRTUROs mode of action and he has also been conferred with “Swiss-TB prize” by Switzerland’s Society of Pneumology for outstanding scientific research in the year 2005.

Dr. Koul is a well-known and respected expert in Infectious diseases with &35 peer-reviewed publications in leading journals like Nature and Science, > 40 presentations at International congress and more than 30 patents to this credit. He and his research team at Janssen have also discovered several new drugs (currently in clinical development) for diseases ranging from viral bronchiolitis/infections, novel antibiotics to animal health. Prior to Janssen, he worked in Germany in a biotech company on the development of kinase inhibitors for oncology and other diseases. Dr. Koul is a visiting professor at Faculty of Sciences at Free University of Amsterdam, Netherlands. He has featured in Voice of America’s scientific radio news analysis on challenges in drug development for neglected diseases.

Related Journals & Conferences :